↓ Skip to main content

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

patent
3 patents

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
26 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
Published in
Journal for Immunotherapy of Cancer, November 2015
DOI 10.1186/2051-1426-3-s2-p376
Authors

Matthew Taylor, Scott Antonia, Johanna Bendell, Emiliano Calvo, Dirk Jäger, Filippo de Braud, Patrick A Ott, M Catherine Pietanza, Leora Horn, Dung T Le, Michael A Morse, José A López-Martin, Paolo A Ascierto, Olaf Christensen, Jason S Simon, Chen-Sheng Lin, Joseph Paul Eder

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 26 100%

Demographic breakdown

Readers by professional status Count As %
Other 2 8%
Student > Doctoral Student 1 4%
Student > Master 1 4%
Unknown 22 85%
Readers by discipline Count As %
Arts and Humanities 1 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Medicine and Dentistry 1 4%
Unknown 23 88%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 October 2021.
All research outputs
#5,446,210
of 25,371,288 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,421
of 3,421 outputs
Outputs of similar age
#69,025
of 296,789 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#12
of 98 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,421 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,789 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.